EUVIMEDOpdag EUVIMED
Crossref

CaMKIIα hub ligands are unable to reverse known phenotypes in Angelman syndrome mice

Stine J Gauger iD, Maria E K Lie iD, Ilse Wallaard iD, Yongsong Tian iD, Aleš Marek iD, Bente Frølund iD, Geeske M van Woerden iD, Ype Elgersma iD, Birgitte R Kornum iD, Petrine Wellendorph iD

Basic & Clinical Pharmacology & Toxicology · 2025

DOI: 10.1111/bcpt.14112 ↗

At a glance

Journal article in Basic & Clinical Pharmacology & Toxicology, 2025. Written by Stine J Gauger and 9 co-authors. Institution: Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Major MEDLINE topics: Angelman Syndrome, Calcium-Calmodulin-Dependent Protein Kinase Type 2, Phenotype, Disease Models, Animal. 61 references. Funded by: Novo Nordisk Foundation, Lundbeck Foundation, Novo Nordisk Fonden.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Angelman Syndrome (AS) is a neurodevelopmental disorder caused by the loss of function of ubiquitin‐protein ligase E3A (UBE3A), resulting in marked changes in synaptic plasticity. In AS mice, a dysregulation of Ca 2+ /calmodulin‐dependent protein kinase II alpha (CaMKIIα) was previously described. This has been convincingly validated through genetic rescue of prominent phenotypes in mouse cross‐breeding experiments. Selective ligands that specifically stabilize the CaMKIIα central association (hub) domain and affect different conformational states in vitro are now available. Two of these ligands, 3‐hydroxycyclopent‐1‐enecarboxylic acid (HOCPCA) and ( E )‐2‐(5‐hydroxy‐2‐phenyl‐5,7,8,9‐tetrahydro‐6 H ‐benzo[7]annulen‐6‐ylidene)acetic acid (Ph‐HTBA), confer neuroprotection after ischemic stroke in mice where CaMKIIα is known to be dysregulated. Here, we sought to investigate whether pharmacological modulation with these prototypical CaMKIIα hub ligands presents a viable approach to alleviate AS symptoms. We performed an in vivo functional evaluation of AS mice treated for a total of 14 days with either HOCPCA or Ph‐HTBA (7 days pre‐treatment and 7 days of behavioural assessment). Both compounds were well‐tolerated but unable to revert robust phenotypes of motor performance, anxiety, repetitive behaviour or seizures in AS mice. Biochemical experiments subsequently assessed CaMKIIα autophosphorylation in AS mouse brain tissue. Taken together our results indicate that pharmacological modulation of CaMKIIα via the selective hub ligands used here is not a viable treatment strategy in AS.

Subjects

MeSH terms (MEDLINE)

Angelman SyndromeCalcium-Calmodulin-Dependent Protein Kinase Type 2PhenotypeDisease Models, AnimalAnimalsMiceLigandsMaleBehavior, AnimalUbiquitin-Protein LigasesMice, Inbred C57BLNeuroprotective AgentsFemaleBrain

Author keywords

(E)‐2‐(5‐hydroxy‐2‐phenyl‐5,7,8,9‐tetrahydro‐6H‐benzo[7]annulen‐6‐ylidene)aceti…3‐hydroxycyclopent‐1‐enecarboxylic acid (HOCPCA)AS‐related behaviourAngelman syndrome (AS)Ca2+/CaM‐dependent kinase II alpha (CaMKIIα)hub domain

Substances

Calcium-Calmodulin-Dependent Protein Kinase Type 2LigandsCamk2a protein, mouseUbiquitin-Protein LigasesUbe3a protein, mouseNeuroprotective Agents

Authors and institutions

  • Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Clinical Genetics, Center of Expertise for Neurodevelopment (ENCORE), Rotterdam, The Netherlands.
  • Institute of Organic Chemistry and Biochemistry, The Czech Academy of Sciences, Prague 6, Czech Republic.
  • Department of Neuroscience, Center of Expertise for Neurodevelopment (ENCORE), Rotterdam, The Netherlands.
  • Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

ORCID profiles: Stine J Gauger, Maria E K Lie, Ilse Wallaard, Yongsong Tian, Aleš Marek, Bente Frølund, Geeske M van Woerden, Ype Elgersma, Birgitte R Kornum, Petrine Wellendorph

Funding

  • Novo Nordisk Foundation
  • Lundbeck Foundation
  • Novo Nordisk Fonden
  • Lundbeckfonden

Cite

APA

Gauger, S. J., Lie, M. E. K., Wallaard, I., Tian, Y., Marek, A., Frølund, B., van Woerden, G. M., Elgersma, Y., Kornum, B. R., & Wellendorph, P. (2025). CaMKIIα hub ligands are unable to reverse known phenotypes in Angelman syndrome mice. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.14112

Vancouver

Gauger SJ, Lie MEK, Wallaard I, Tian Y, Marek A, Frølund B, et al. CaMKIIα hub ligands are unable to reverse known phenotypes in Angelman syndrome mice. Basic & Clinical Pharmacology & Toxicology. 2025. doi:10.1111/bcpt.14112

BibTeX
@article{Gauger2025,
  author = {Gauger, Stine J and Lie, Maria E K and Wallaard, Ilse and Tian, Yongsong and Marek, Aleš and Frølund, Bente and van Woerden, Geeske M and Elgersma, Ype and Kornum, Birgitte R and Wellendorph, Petrine},
  title = {CaMKIIα hub ligands are unable to reverse known phenotypes in Angelman syndrome mice},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2025},
  doi = {10.1111/bcpt.14112}
}
Start for free →